Population-based studies support the hypothesis that AR may antagonize the detrimental effects of ER signaling, and have shown a consistent inverse association between tumor AR expression and mortality among patients with ER+ breast cancer [7, 12, 14]. Here, ESR1 is linked to breast carcinoma.